
A feasibility trial of the partners at care transitions (PACT) intervention (ISRCTN51154948)

Basic Results Summary

Participant Flow:



Baseline characteristics of participants:

Variable		Intervention (n=95)	Control (n=66)	AII (n=161)
Participant Status	Patient	85 (89.5%)	56 (84.8%)	141 (87.6%)
	Informal carer	10 (10.5%)	10 (15.2%)	20 (12.4%)
Gender	Male	48 (50.5%)	18 (27.3%)	66 (41.0%)
	Female	47 (49.5%)	48 (72.7%)	95 (59.0%)
Age (years)	N	95 (100.0%)	66 (100.0%)	161 (100.0%)
	Mean (SD)	83.3 (5.2)	83.7 (4.8)	83.4 (5.0)
	Median (IQR)	83.0 (79, 87)	83.5 (81, 86)	83.0 (79, 87)
	Min, Max	75.0, 95.0	75.0, 95.0	75.0, 95.0
Ethnicity	White British	91 (95.8%)	66 (100.0%)	157 (97.5%)
	White Irish	2 (2.1%)	0 (0.0%)	2 (1.2%)
	White other	1 (1.1%)	0 (0.0%)	1 (0.6%)
	Pakistani	1 (1.1%)	0 (0.0%)	1 (0.6%)
First Language	English	88 (92.6%)	61 (92.4%)	149 (92.5%)
	Other	2 (2.1%)	0 (0.0%)	2 (1.2%)
	Not reported	5 (5.3%)	5 (7.6%)	10 (6.2%)
Live in status	Alone	31 (32.6%)	27 (40.9%)	58 (36.0%)
	Alone with regular support from family	16 (16.8%)	16 (24.2%)	32 (19.9%)
	With spouse/partner	44 (46.3%)	17 (25.8%)	61 (37.9%)
	With son/daughter (in-law)	3 (3.2%)	4 (6.1%)	7 (4.3%)
	With brother/sister	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Other	1 (1.1%)	2 (3.0%)	3 (1.9%)
Has daily carers	Yes	10 (10.5%)	10 (15.2%)	20 (12.4%)
	No	83 (87.4%)	56 (84.8%)	139 (86.3%)
	Not reported	2 (2.1%)	0 (0.0%)	2 (1.2%)
Number of previous hospital admissions in the previous 12 months	N	90 (94.7%)	65 (98.5%)	155 (96.3%)
	Mean (SD)	0.8 (1.2)	1.0 (1.3)	0.9 (1.3)
	Median (IQR)	0.0 (0, 1)	1.0 (0, 2)	0.0 (0, 2)
	Min, Max	0.0, 5.0	0.0, 7.0	0.0, 7.0
	Not reported	5 (5.3%)	1 (1.5%)	6 (3.7%)
Number of previous hospital admissions in the previous 12 months	0	52 (54.7%)	30 (45.5%)	82 (50.9%)
	1	16 (16.8%)	18 (27.3%)	34 (21.1%)
	2	13 (13.7%)	12 (18.2%)	25 (15.5%)
	3	4 (4.2%)	0 (0.0%)	4 (2.5%)
	4+	5 (5.3%)	5 (7.6%)	10 (6.2%)
	Not reported	5 (5.3%)	1 (1.5%)	6 (3.7%)
Method of index admission	Emergency	88 (92.6%)	64 (97.0%)	152 (94.4%)
	Elective	2 (2.1%)	0 (0.0%)	2 (1.2%)
	Other	5 (5.3%)	2 (3.0%)	7 (4.3%)
EQ5D-5L score	N	95 (100.0%)	66 (100.0%)	161 (100.0%)
	Mean (SD)	0.512 (0.3)	0.441 (0.3)	0.483 (0.3)
	Median (IQR)	0.567 (0.3, 0.7)	0.514 (0.2, 0.7)	0.553 (0.3, 0.7)
	Min, Max	-0.043, 1	-0.51, 1	-0.51, 1
EQ5D VAS	N	95 (100.0%)	66 (100.0%)	161 (100.0%)
	Mean (SD)	50.1 (21.1)	56.2 (20.0)	52.6 (20.8%)
	Median (IQR)	50.0 (35, 65)	55.0 (40, 75)	50.0 (40, 70)
	Min, Max	5, 99	10, 100	5, 100
Barthel Index	N	95 (100.0%)	66 (100.0%)	161 (100.0%)
	Mean (SD)	14.3 (4.3)	13.0 (4.5)	13.8 (4.4)

	Median (IQR) Min, Max	15.0 (10, 18) 4, 20	14.0 (10, 17) 1, 20	15.0 (10, 17) 1, 20
Functional Co-Morbidity Index	N Mean (SD) Median (IQR) Min, Max	95 (100.0%) 3.7 (2.1) 3.0 (2, 5) 0, 10	66 (100.0%) 3.5 (2.0) 3.0 (2, 4) 0, 9	161 (100.0%) 3.6 (2.0) 3.0 (2, 5) 0, 10
Number of Comorbidities	0 1 2 3 4 5 6+	2 (2.1%) 9 (9.5%) 17 (17.9%) 22 (23.2%) 19 (20.0%) 13 (13.7%) 13 (13.7%)	4 (6.1%) 3 (4.5%) 15 (22.7%) 19 (28.8%) 9 (13.6%) 4 (6.1%) 12 (18.2%)	6 (3.7%) 12 (7.5%) 32 (19.9%) 41 (24.5%) 28 (17.4%) 17 (10.6%) 25 (15.5%)
Comorbidity [†]	Arthritis Osteoporosis Asthma COPD, ARDS or emphysema Angina Congestive Heart Failure Heart Attack Neurological Disease	48 (50.5%) 14 (14.7%) 14 (14.7%) 19 (20.0%) 11 (11.6%) 30 (31.6%) 21 (22.1%) 0 (0.0%)	34 (51.5%) 17 (25.8%) 9 (13.6%) 8 (12.1%) 5 (7.6%) 16 (24.2%) 5 (7.6%) 5 (7.6%)	82 (50.9%) 31 (19.3%) 23 (14.3%) 27 (16.8%) 16 (9.9%) 46 (28.6%) 26 (16.2%) 5 (3.1%)
	Stroke/TIA Peripheral Vascular Disease Diabetes Upper gastrointestinal disease Depression	26 (27.4%) 8 (8.4%) 28 (29.5%) 14 (14.7%) 7 (7.4%)	16 (24.2%) 3 (4.6%) 16 (24.2%) 9 (13.6%) 8 (12.1%)	42 (26.1%) 11 (6.8%) 44 (27.3%) 23 (14.3%)
	Anxiety/ Panic Disorders Visual impairment Hearing impairment Degenerative disk disease	7 (7.4%) 42 (44.2%) 27 (28.4%) 20 (21.1%)	12 (18.2%) 38 (57.6%) 16 (24.2%) 7 (10.6%)	19 (11.8%) 80 (49.7%) 43 (26.7%) 27 (16.8%)
	Obesity/ BMI >30	13 (13.7%)	4 (6.1%)	17 (10.6%)

[†]Categories are not mutually exclusive

Outcome Measures:

Outcome Measure	Intervention (n=95)		Control (n=66)		Overall (n=161)	
	n(%)	Score*	n(%)	Score*	n(%)	Score*
Emergency	11(70)	Score	11(/0)	Score	11(70)	30016
Readmissions						
30-days post-discharge	87 (91.6%)	0.2 (0.4)	61 (92.4%)	0.2 (0.6)	148 (91.9%)	0.2 (0.5)
60-days post-discharge	87 (91.6%)	0.3 (0.6)	61 (92.4%)	0.4 (0.7)	148 (91.9%)	0.3 (0.6)
90-days post-discharge	87 (91.6%)	0.4 (0.6)	61 (92.4%)	0.5 (0.7)	148 (91.9%)	0.4 (0.7)
		1		1	ı	
EQ5D-5L						
T1	68 (71.6%)	0.495 (0.3)	48 (72.7%)	0.506 (0.3)	116 (72.0%)	0.499 (0.3)
T2	51 (53.7%)	0.512 (0.3)	40 (60.6%)	0.484 (0.3)	91 (56.5%)	0.500 (0.3)
T3	11 (11.6%)	0.416 (0.4)	16 (24.2%)	0.587 (0.3)	27 (16.8%)	0.517 (0.3)
EQ5D VAS						
T1	69 (72.6%)	58.2 (18.0)	47 (71.2%)	53.7 (23.3)	116 (72.0%)	56.4 (20.3)
T2	53 (55.8%)	60.5 (20.6)	39 (59.1%)	60.2 (20.0)	92 (57.1%)	60.4 (20.2)
T3	11 (11.6%)	58.2 (20.3)	16 (24.2%)	67.8 (17.9)	27 (16.8%)	63.9 (19.1)
PACT-M						
T1	62 (65.3%)	50.8 (9.2)	38 (57.6%)	49.5 (9.6)	100 (62.1%)	50.3 (9.3)
T2	45 (47.4%)	54.4 (8.3)	34 (51.6%)	53.1 (9.0)	79 (49.1%)	53.8 (8.6)
T3	9 (9.5%)	51.3 (8.3)	11 (16.7%)	57.5 (6.6)	20 (12.4%)	54.7 (7.9)
CTM-3						
T1	63 (66.3%)	68.2 (18.6)	43 (65.2%)	64.0 (17.5)	106 (65.8%)	66.5 (18.2)
T2	45 (47.4%)	67.5 (18.5)	33 (50%)	63.1 (17.0)	78 (48.4%)	65.7 (17.9)
T3	11 (11.6%)	68.7 (19.8)	13 (19.7%)	63.2 (18.9)	24 (14.9%)	65.7 (19.1)

Adverse Events:

For the PACT feasibility study (WP5) safety was assessed by serious adverse events (SAEs) including deaths. The death of participants is expected within the study population. Non-serious adverse events (AEs) were not reportable as in this patient population, acute illness resulting in hospitalisation, new medical problems and deterioration or existing medical problems are not unlikely. Details of definitions of SAEs are outlined in the study protocol.

Relatedness of SAE	Death pre discharge			Death post discharge		
	Intervention	Control	Total	Intervention	Control	Total
	n= 4	n= 3	n= 7	n = 9	n = 5	14
Unlikely to be related	3 (75.0%)	1 (33.3%)	4 (57.1%)	5 (55.6%)	3 (60.0%)	8 (57.1%)
Not related	1 (25.0%)	2 (66.7%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Not reported	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (44.4%)	2 (40.0%)	6 (42.9%)